PT3654989T - Uso de cladribina para o tratamento de uma doença neuromuscular autoimune - Google Patents

Uso de cladribina para o tratamento de uma doença neuromuscular autoimune

Info

Publication number
PT3654989T
PT3654989T PT187395934T PT18739593T PT3654989T PT 3654989 T PT3654989 T PT 3654989T PT 187395934 T PT187395934 T PT 187395934T PT 18739593 T PT18739593 T PT 18739593T PT 3654989 T PT3654989 T PT 3654989T
Authority
PT
Portugal
Prior art keywords
cladribin
treatment
neuromuscular disease
autoimmune neuromuscular
autoimmune
Prior art date
Application number
PT187395934T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Chord Therapeutics Sa C/O Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa C/O Ares Trading Sa filed Critical Chord Therapeutics Sa C/O Ares Trading Sa
Publication of PT3654989T publication Critical patent/PT3654989T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PT187395934T 2017-07-21 2018-06-28 Uso de cladribina para o tratamento de uma doença neuromuscular autoimune PT3654989T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease

Publications (1)

Publication Number Publication Date
PT3654989T true PT3654989T (pt) 2024-02-28

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187395934T PT3654989T (pt) 2017-07-21 2018-06-28 Uso de cladribina para o tratamento de uma doença neuromuscular autoimune

Country Status (16)

Country Link
US (2) US12171775B2 (https=)
EP (2) EP4292663A3 (https=)
JP (1) JP7186214B2 (https=)
CA (1) CA3095893A1 (https=)
DK (1) DK3654989T3 (https=)
ES (1) ES2974423T3 (https=)
FI (1) FI3654989T3 (https=)
GB (1) GB2564717A (https=)
HR (1) HRP20240282T1 (https=)
HU (1) HUE066238T2 (https=)
LT (1) LT3654989T (https=)
PL (1) PL3654989T3 (https=)
PT (1) PT3654989T (https=)
RS (1) RS65246B1 (https=)
SI (1) SI3654989T1 (https=)
WO (1) WO2019016505A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
TW202541818A (zh) 2023-12-14 2025-11-01 瑞士商亞利斯貿易公司 用於治療重症肌無力之克拉屈濱(cladribine)療程

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
AU2003287664A1 (en) * 2002-11-22 2004-06-18 Transclick, Inc. System and method for language translation via remote devices
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
JP7186214B2 (ja) 2022-12-08
JP2020527156A (ja) 2020-09-03
RS65246B1 (sr) 2024-03-29
HRP20240282T1 (hr) 2024-05-10
US20250302858A1 (en) 2025-10-02
WO2019016505A1 (en) 2019-01-24
DK3654989T3 (da) 2024-02-26
EP4292663A2 (en) 2023-12-20
EP4292663A3 (en) 2024-03-20
HUE066238T2 (hu) 2024-07-28
PL3654989T3 (pl) 2024-05-20
LT3654989T (lt) 2024-03-25
GB2564717A (en) 2019-01-23
GB201711800D0 (en) 2017-09-06
SI3654989T1 (sl) 2024-06-28
EP3654989A1 (en) 2020-05-27
CA3095893A1 (en) 2019-01-24
ES2974423T3 (es) 2024-06-27
US20200163986A1 (en) 2020-05-28
US12171775B2 (en) 2024-12-24
FI3654989T3 (fi) 2024-03-21
EP3654989B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
FR21C1039I2 (fr) Composés destinés à traiter l'amyotrophie spinale
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
PT3631454T (pt) Tratamento de tumores positivos para lag-3
IL256166B (en) Compounds for use in treating neuromuscular disorders
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
PT3562486T (pt) Uso de dexmedetomidina sublingual para o tratamento da agitação
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
PT3681872T (pt) Beta-hidroxietilaminas substituídas com heteroarilo para utilização no tratamento de hiperglicemia
IL272821A (en) TIM-3 antagonists for the treatment and diagnosis of cancer
EP3636246A4 (en) COSMETIC PREPARATION WITH WATER-IN-OIL EMULSION
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
IL256103B (en) Compositions and methods for treating celiac sprue disease
IL283511A (en) Dendrimer for therapy and imaging
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
HUE064813T2 (hu) NK-3 receptor antagonisták testzsírfelesleg terápiás vagy kozmetikai kezelésére
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
EP3592377A4 (en) DOSAGE FORMS OF TISSUE KALLIKREIN 1
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
EP3840989C0 (en) SLIDING CENTER CONSOLE
EP3806844A4 (en) DOTA COMPOUNDS AND RELATED USES
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PT3654989T (pt) Uso de cladribina para o tratamento de uma doença neuromuscular autoimune
EP3790928A4 (en) Medical lubricant